Transport Pharmaceuticals is a clinical stage, privately held Delaware Corporation known for its innovative approach to the convergence of drugs and medical devices for the topical treatment of dermatological conditions. The company's late stage lead product, SoloVir™ ETS, has shown promise as a potential breakthrough for the treatment of herpes labialis (cold sores), addressing a market with significant unmet medical needs. Established in 1999, the company operates in the Health Care and Pharmaceutical industries, with its headquarters based in the United States. The most recent investment of $99.00K in debt financing was secured on 06 October 2009. Notably, the specific investors for this latest round of financing were not disclosed. Transport Pharmaceuticals presents an intriguing opportunity in the pharmaceutical sector, with its focus on addressing underserved dermatological conditions through its innovative product offerings.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | $99.00K | - | 06 Oct 2009 | |
| Debt Financing | $200.00K | - | 12 Aug 2009 | |
| Debt Financing | $500.00K | - | 01 Jul 2009 | |
| Debt Financing | $1.00M | - | 22 Apr 2009 |
No recent news or press coverage available for Transport Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
